Primary Hyperoxaluria Type 1 (PH1)
7
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
43%
3 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Long Term Extension Study in Patients With Primary Hyperoxaluria
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1